These preclinical findings are consistent with immunohistological analysis of human biopsy specimens taken from patients receiving immunotherapy, where nonresponding lesions show a peripheral distribution of CD8+ T cells and responders show clear signs of CD8+ T cells that penetrate the tumor [37–39]. Here, CD8A is linked to neoplasm.